Healthy Skepticism Library item: 6612

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: Journal Article

Servier claims that “3 months treatment of obesity with Adifax reduces high risk visceral fat by 31%”
MaLAM Australian News 1995 Dec; 3:(12):1

Abstract:

Servier is extensively promoting Adifax (dexfenfluramine) in Australia for weight reduction. However there are serious safety concerns about this product which raises the question of its risk/benefit ratio.

Keywords:
*analysis/Australia/developed countries/Adifax/dexfenfluramine/Servier/safety & risk information/ obesity/ appetite stimulants and suppressants/MaLAM/Medical Lobby for Appropriate Marketing/PROMOTION AND HEALTH NEEDS: PROMOTION IN DEVELOPED COUNTRIES/PROMOTION IN SPECIFIC THERAPEUTIC AREAS: WEIGHT GAIN AND LOSS